Colin D Biggin

Chief Executive Officer, Managing Director / Clarity Pharmaceuticals

Dr Biggin has over 15 years of radiopharmaceutical development and commercialisation experience. Dr Biggin previously served with Algeta ASA during the development and commercialisation of its product Xofigo (radium-223 dichloride) for metastatic prostate cancer, which was approved by the FDA in 2013. Prior to joining the Company, Dr Biggin also consulted to a range of biotech and large pharmaceutical companies developing radiopharmaceuticals.

Lists and Charts

Total Shareholder Return as at 02/12/24

Rank	Company	1 Yr	5 Yr
19^th	Petratherm">Petratherm	360.61%	40.77%
20^th	Chilwa Minerals">Chilwa Minerals	357.87%	0%
21^st	Clarity Pharmaceuticals">Clarity Pharmaceuticals	351.19%	0%
22^nd	Trigg Minerals">Trigg Minerals	349.92%	-8.68%
23^rd	Rimfire Pacific Mining">Rimfire Pacific Mining	340.24%	85.63%

View Full List

1767 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®

Share Transactions

Person Activity

NEW ROLE: Chief Executive Officer, Managing Director, Clarity Pharmaceuticals

07 Apr 2022

Related Information

Access to our data for Colin D Biggin is only available to paid subscribers with Data & Insights access.

Data & Insights is Western Australia's most accurate and comprehensive business listings and searchable database.

Colin D Biggin is linked to 1 organisation which is included in 1 list - Public Companies - non WA.

To see the data you will need to Subscribe.